Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Nab-paclitaxel + Pembrolizumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
| Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, HNSCC, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive cervical cancer, with gemcitabine and cisplatin for biliary tract cancer, with chemoradiation for cervical cancer, with carboplatin and paclitaxel for endometrial carcinoma, with paclitaxel with or without bevacizumab for epithelial ovarian, Fallopian tube, and peritonium cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | triple-receptor negative breast cancer | sensitive | Nab-paclitaxel + Pembrolizumab | Guideline | Actionable | Combination of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent unresectable or stage IV (M1) CD274 (PD-L1)-positive (CPS >/= 10) triple-receptor negative breast cancer (category 1) (NCCN.org). | detail... |
| CD274 positive | lung adenocarcinoma | predicted - sensitive | Nab-paclitaxel + Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a lung adenocarcinoma patient with CD274 (PD-L1) expression of 30% and harboring CD74-ROS1 and ROS1 G2032K demonstrated a partial response after being treated with the combination therapy of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) for two cycles (PMID: 32208297). | 32208297 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05852691 | Phase II | Nab-paclitaxel + Tobemstomig Nab-paclitaxel + Pembrolizumab | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | POL | ITA | ISR | HUN | ESP | DEU | CZE | BRA | AUS | ARG | 5 |
| NCT02752685 | Phase II | Nab-paclitaxel + Pembrolizumab | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
| NCT04297605 | Phase I | Pembrolizumab + Pemetrexed Disodium Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 | Recruiting | USA | 0 |
| NCT04964960 | Phase II | Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab | Pembro+Chemo in Brain Mets | Terminated | USA | 0 |
| NCT02733250 | Phase Ib/II | Nab-paclitaxel + Pembrolizumab | Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) | Completed | CAN | 0 |
| NCT04895358 | Phase III | Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 11 |
| NCT03240016 | Phase II | Nab-paclitaxel + Pembrolizumab | Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer | Completed | USA | 0 |
| NCT05382286 | Phase III | Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Gemcitabine + Pembrolizumab Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT06492759 | Phase II | Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
| NCT05233696 | Phase II | Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | Withdrawn | USA | 0 |
CKB BOOST